Neuroendocrine Tumors (NETs) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Neuroendocrine Tumors (NETs) Emerging Therapy and TPP Insights

Thelansis’s “Neuroendocrine Tumors (NETs) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Neuroendocrine Tumors (NETs) Overview

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms arising from secretory cells of the diffuse neuroendocrine system, occurring most commonly in the gastroenteropancreatic tract and lungs, characterised by variable hormonal secretory activity and somatostatin receptor overexpression. Well-differentiated NETs are graded G1 through G3 by Ki-67 proliferative index, while poorly differentiated neuroendocrine carcinomas represent a distinct aggressive entity. Functioning tumors produce hormonal syndromes including carcinoid syndrome, insulinoma, and gastrinoma, while non-functioning tumors present incidentally or with mass-effect symptoms. Diagnosis integrates specific hormonal assays, DOTATATE PET-CT for superior lesion detection and staging, and emerging mRNA-based blood assays including NETest; chromogranin A is increasingly de-emphasised given poor specificity, frequent false positivity with proton pump inhibitor use, and limited monitoring utility. Surgical resection remains the cornerstone of curative intent. Somatostatin analogues octreotide and lanreotide provide antiproliferative and antisecretory benefits. Lutetium-177 DOTATATE, supported by NETTER-2 trial data, is now established as first-line standard of care for advanced, high-burden somatostatin receptor-positive Grade 2 and Grade 3 GEP-NETs, representing a fundamental repositioning from later-line therapy. Everolimus and sunitinib address pancreatic NETs specifically, while telotristat ethyl controls refractory carcinoid syndrome diarrhoea. Prognosis varies with grade and disease extent; multidisciplinary management and patient-centred symptom control are integral to optimising outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Neuroendocrine Tumors (NETs) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026